Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted) (2020 - 2026)

Atea Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.57 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 42.5% to -$0.57 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.11 through Mar 2026, down 27.88% year-over-year, with the annual reading at -$1.94 for FY2025, 3.0% up from the prior year.
  • EPS (Weighted Average and Diluted) came in at -$0.57 for Q1 2026, roughly flat from -$0.57 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.1 in Q3 2022 to a low of -$0.75 in Q1 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.43 (2023), against an average of -$0.44.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 70.59% in 2022 against a maximum downside of 2000.0% in 2022.
  • Atea Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.41 in 2022, then dropped by 14.63% to -$0.47 in 2023, then increased by 14.89% to -$0.4 in 2024, then crashed by 42.5% to -$0.57 in 2025, then fell by 0.0% to -$0.57 in 2026.
  • Per Business Quant, the three most recent readings for AVIR's EPS (Weighted Average and Diluted) are -$0.57 (Q1 2026), -$0.57 (Q4 2025), and -$0.53 (Q3 2025).